Triple negative breast carcinoma: The good, the bad and the ugly

Diagnostic Histopathology

Volumn 18, Issue 5, 2012, Pages 210-216

  Kandil, Dina ^a   Khan, Ashraf ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Adenoid cystic carcinoma; Basal type carcinoma; CK5 6; EGFR; Hereditary; IMP 3; Ki 67; Medullary carcinoma; Metaplastic carcinoma; Triple negative breast cancer

Indexed keywords

BETA4 INTEGRIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CAVEOLIN 1; CAVEOLIN 2; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; MASPIN; OSTEOPONTIN; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN P63; SOMATOMEDIN B; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN;

ADENOID CYSTIC CARCINOMA; ARTICLE; BASAL LIKE BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMA; CARCINOMA IN SITU; CELL DIFFERENTIATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE COURSE; DISTANT METASTASIS; FAMILIAL CANCER; HEREDITARY BREAST CANCER; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MEDULLARY CARCINOMA; MESENCHYME CELL; METAPLASTIC CARCINOMA; ONCOGENE C KIT; SQUAMOUS CELL; TISSUE SECTION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84859948408     PISSN: 17562317     EISSN: 18767621     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2012.02.001     Document Type: Article

References (37)

1. Trivers K.F., Lund M.J., Porter P.L., et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control Sep 2009, 20:1071-1082.
2. Phipps A.I., Chlebowski R.T., Prentice R., et al. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev Mar 2011, 3:454-463.
3. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer May 1 2007, 109:1721-1728.
4. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature Aug 17 2000, 406:747-752.
5. Brenton J.D., Carey L.A., Ahmed A.A., Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol Oct 10 2005, 23:7350-7360.
6. Mc L.P., Tennant R., Sarokhan J. Adenoid cystic carcinoma of the breast; report of a case with unusual features. Surgery Jun 1953, 33:905-908.
7. Sumpio B.E., Jennings T.A., Merino M.J., Sullivan P.D. Adenoid cystic carcinoma of the breast. Data from the Connecticut Tumor Registry and a review of the literature. Ann Surg Mar 1987, 205:295-301.
8. Ghabach B., Anderson W.F., Curtis R.E., Lavigne J.A., Dores G.M. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res 2010, 12:R54.
9. Rabban J.T., Swain R.S., Zaloudek C.J., Chase D.R., Chen Y.Y. Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers. Mod Pathol Oct 2006, 19:1351-1357.
10. Ridolfi R.L., Rosen P.P., Port A., Kinne D., Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer Oct 1977, 40:1365-1385.
11. Pedersen L., Holck S., Schiodt T., Zedeler K., Mouridsen H.T. Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis. Eur J Cancer 1994, 30A:1792-1797.
12. Rosen P.P., Menendez-Botet C.J., Nisselbaum J.S., et al. Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer Res Nov 1975, 35(11 Pt 1):3187-3194.
13. Vincent-Salomon A., Gruel N., Lucchesi C., et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007, 9:R24.
14. Teixeira M.R., Qvist H., Bohler P.J., Pandis N., Heim S. Cytogenetic analysis shows that carcinosarcomas of the breast are of monoclonal origin. Genes Chromosomes Cancer Jun 1998, 22:145-151.
15. Wada H., Enomoto T., Tsujimoto M., Nomura T., Murata Y., Shroyer K.R. Carcinosarcoma of the breast: molecular-biological study for analysis of histogenesis. Hum Pathol Nov 1998, 29:1324-1328.
16. Dunne B., Lee A.H., Pinder S.E., Bell J.A., Ellis I.O. An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol Oct 2003, 34:1009-1015.
17. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature Dec 21-28 1995, 378:789-792.
18. Collins L.C., Martyniak A., Kandel M.J., et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol Jul 2009, 33:1093-1097.
19. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res Apr 1 2009, 15:2302-2310.
20. Eerola H., Heinonen M., Heikkila P., et al. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2008, 10:R17.
21. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet May 24 1997, 349:1505-1510.
22. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A Sep 11 2001, 98:10869-10874.
23. Kirsh V.A., Chiarelli A.M., Edwards S.A., et al. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Institute Jun 22 2011, 103:942-950.
24. Van den Eynden G.G., Smid M., Van Laere S.J., et al. Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer. Clin Cancer Res May 15 2008, 14:2944-2952.
25. Van de Rijn M., Perou C.M., Tibshirani R., et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol Dec 2002, 161:1991-1996.
26. Liu D., He J., Yuan Z., et al. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol (Northwood, London, England) Jan 25 2011, [Epub ahead of print 1/2010].
27. Jacquemier J., Padovani L., Rabayrol L., et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol Nov 2005, 207:260-268.
28. Jiang Z., Chu P.G., Woda B.A., et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol Jul 2006, 7:556-564.
29. Walter O., Prasad M., Lu S., Quinlan R.M., Edmiston K.L., Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol Nov 2009, 40:1528-1533.
30. Lu S., Simin K., Khan A., Mercurio A.M. Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res Feb 15 2008, 14:1050-1058.
31. Ryden L., Jirstrom K., Haglund M., Stål O., Fernö M. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat 2010, Apr, 120:491-498.
32. Elsheikh S.E., Green A.R., Rakha E.A., et al. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer Jul 22 2008, 99:327-334.
33. Umekita Y.D., Ohi Y.D., Souda M.D., et al. Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer. Diagn Pathol 2011 Apr 16, 6:36.
34. Wang X., Chao L., Ma G., et al. Increased expression of osteopontin in patients with triple-negative breast cancer. Eur J Clin Invest Jun 2008, 38:438-446.
35. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res Aug 15 2004, 10:5367-5374.
36. Cheang M.C., Voduc D., Bajdik C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res Mar 1 2008, 14:1368-1376.
37. Hicks D.G., Short S.M., Prescott N.L., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol Sep 2006, 30:1097-1104.